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INTRODUCTION
High-dose therapy with peripheral blood stem cell
(PBSC) or bone marrow support for advanced breast cancer
has resulted in high response rates, including complete
response (CR) rates of >50%, but only 15% to 20% of
responding women achieve long-term disease-free surv i v a l
[1-6]. These results demonstrate that this therapy is unable
to overcome drug resistance in the majority of patients.
Therefore, the need to circumvent drug resistance remains
an important goal in the treatment of breast cancer. 
Investigational approaches designed to overcome dru g
resistance include evaluation of new chemotherapeutic
p reparative regimens, use of sequential high-dose therapy,
immune treatment modalities, and inclusion of agents that
may reverse resistance to therapy [7-9]. Dose intensity has
been shown to be important in the treatment of metastatic
breast cancer [10,11], and experimental studies have demon-
strated that drug resistance can be at least partially overc o m e
by dose escalation [12]. Alkylating agents (which universally
are a component of high-dose therapy) have been shown to
have a steep dose-response curve with a generally linear
relationship between dose and log cell kill [12,13].
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ABSTRACT
We conducted the first phase 2 and pharmacologic study to evaluate the combination of novobiocin (a c o u m e ro m y c i n
antibiotic that has been shown to augment alkylating agent cytotoxicity in experimental models) and high-dose
cyclophosphamide and thiotepa followed by autologous marrow support in women with chemosensitive advanced
b reast cancer. Its aims were (1) to determine pro g re s s i o n - f ree survival (PFS) and overall survival (OS), (2) to evalu-
ate the pharmacokinetics of cyclophosphamide and thiotepa, and (3) to measure the ability of novobiocin to re v e r s e
alkylator drug resistance in vitro. Forty-one women with chemotherapy-responsive advanced breast cancer re c e i v e d
cyclophosphamide (4 g/m2) for peripheral blood stem cell mobilization (treatment 1) followed by high-dose
cyclophosphamide (1.5 g/m2 per day for 4 days), thiotepa (200 mg/m2 per day for 4 days), and novobiocin (4 g/day
orally for 7 days) (treatment 2) and autologous marrow support. The median PFS was 10 months (range, 0.2-70.6
months) and OS, 21.5 months (range, 0.2-70.6 months). There was no statistically significant relationship between
PFS or OS and are a - u n d e r- t h e - c u rve values of cyclophosphamide, thiotepa, or 4-hydroxycyclophosphamide. Patient
plasma samples (n = 12) obtained during novobiocin therapy were able to reverse alkylator drug resistance in an in
v i t ro colony-forming assay. Correlative laboratory studies in an in vitro model system demonstrated that patient
plasma after novobiocin treatment resulted in the magnitude of resistance reversal that had been predicted by prior
p reclinical experiments. Clinically, however, this activity of novobiocin did not translate into a substantial increase in
PFS or OS compared with historical controls treated with high-dose alkylator therapy alone. 
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Alkylating agents induce cell death by direct DNA dam-
age, and one possible avenue to augment their activity is
inhibition of DNA re p a i r. The coumeromycin antibiotic
novobiocin has several effects, including inhibition of DNA
re p a i r, on the DNA of pro k a ryotic and eukaryotic cells
[14,15]. Novobiocin has been shown to augment alkylating
agent cytotoxicity in vitro and in vivo, whereas novobiocin
treatment alone has minimal cytotoxicity [15-18]. The activ-
ity of novobiocin in combination with alkylating agents is
schedule-dependent, with synergy occurring when novo-
biocin treatment precedes or is concomitant with alkylator
administration [15,17,19].
T h ree clinical trials that evaluated novobiocin in combi-
nation with alkylating agents have demonstrated that novo-
biocin can safely be given with alkylating agent therapy
[7,20,21]. We previously re p o rted the first phase 1 study of
novobiocin in combination with high-dose cyclophos-
phamide (CTX) and thiotepa plus PBSC/bone marrow re s-
cue in women with metastatic or locally advanced inoperable
b reast cancer [7]. The maximally tolerated dose of novo-
biocin was 4 g/day, mucositis and vomiting being the dose-
limiting toxicities. The severity of mucositis correlated with
novobiocin plasma levels. Plasma levels of novobiocin
> 1 0 0 µg/mL were consistently observed in patients who
received doses of >2 g daily. These plasma levels met or
exceeded in vitro levels that have been shown to augment
cytotoxicity of the alkylators in experimental models [15-19].
This re p o rt summarizes the results of the only phase 2
clinical trial examining novobiocin in combination with
high-dose CTX and thiotepa followed by autologous
PBSC and bone marrow reinfusion in women with chemo-
sensitive advanced breast cancer. The aims of the study
w e re (1) to determine pro g re s s i o n - f ree survival (PFS) and
overall survival (OS), (2) to evaluate the pharm a c o k i n e t i c s
of CTX and thiotepa and their impact on long-term dis-
e a s e - f ree survival, and (3) to measure the ability of novo-
biocin to reverse alkylator drug resistance in an in vitro
assay using patient plasma samples.
PATIENTS AND METHODS
P a t i e n t s
Women between the ages of 18 and 60 years with histo-
logically documented stage IIIB or IV breast cancer, a stable
complete or partial response to induction chemotherapy (as
d e fined by standard Eastern Cooperative Oncology Gro u p
[ECOG] criteria), and ECOG perf o rmance status <2 were
eligible for this study [22]. Tumor level of estrogen or pro-
g e s t e rone receptor was not a criterion for the study. All
patients had to have adequate renal, hepatic, cardiac, pul-
m o n a ry, and hematopoietic re s e rves to undergo high-dose
alkylator therapy. All patients had bone marrow biopsy
results negative for tumor by routine histologic examina-
tion. Conduct of the trial was approved by the Joint Com-
mission on Clinical Investigation of the Johns Hopkins
Hospital. All patients provided written informed consent.
Bone Marrow and PBSC Harv e s t
All patients received 3 to 10 cycles of standard-dose outpa-
tient chemotherapy (doxorubicin-based, n = 37). Marrow was
collected approximately 4 to 6 weeks after initiation of the last
cycle of induction chemotherapy. A mononuclear cell pre p a r a-
tion was obtained after density centrifugation on Ficoll-
Hypaque (Biowhittaker, Walkersville, MD), incubated with
6 0 µg/mL of 4-hydro p e roxycyclophosphamide (4HC), washed,
and frozen in the liquid phase of nitrogen as described [3,23]. 
On day 0, the day after bone marrow harvest, patients
w e re treated with CTX 4 g/m2 intravenously (IV) ( t re a t-
m e n t 1). From day 1 to 14, patients received granulocyte-
m a c rophage colony-stimulating factor at 5 µg/kg per day
subc u t a n e o u s l y. On day 15, the patients underwent a single
6 -hour high-flow-rate leukapheresis to obtain PBSCs; the
l e u k a p h e resis product was cry o p re s e rved as described [24,25].
N ovobiocin, High-Dose Chemotherapy, and
S u p p o rt i v e Care
After blood count re c o v e ry, patients were admitted for
high-dose chemotherapy. Treatment with novobiocin
(Albamycin; Upjohn, Kalamazoo, MI) was initiated on day –10
at a dose of 4 g/day by mouth in 2 divided doses for a total of
14 doses. Immediately after the fourth dose of novobiocin,
patients began high-dose chemotherapy of CTX 1.5 g/m2 p e r
day and thiotepa 200 mg/m2 per day, both given by continu-
ous IV infusion for 4 days from day –8 to day –5 (treatment 2).
Patients received intensive IV hydration as prophylaxis against
CTX-induced hemorrhagic cystitis. PBSCs and purified bone
m a rrow were infused on day –1 and 0, re s p e c t i v e l y. All
patients received prophylactic antibiotic treatment with nor-
floxacin 400 mg orally every 12 hours and vancomycin 500 mg
IV every 12 hours, both initiated on day –3 until re c o v e ry of
n e u t rophils (neutrophil count >500/µL). Packed red blood cell
transfusions were given as needed to keep the hematocrit
>30%, and single-donor platelets were given as needed to
keep the platelet count >20,000/µL. All blood products were
i rradiated to prevent graft-versus-host disease.
Evaluation of To x i c i t y
Patients were evaluated prospectively for toxicity with
daily physica l examinations, hemograms, and blood
chemistries and appropriate radiographs as needed. Left
ventricular ejection fraction was measured via radionuclide
angiography at completion of induction chemotherapy on
day 8 and after hospital discharge. 
P h a r m a c o l o gy and Pharmacokinetics
Blood and urine specimens were collected for determ i n a-
tion of plasma CTX, 4HC/aldophosphamide, and thiotepa
concentrations and urine CTX concentrations. During both
t reatments, blood samples were obtained several times dur-
ing and for 24 hours after CTX infusion as described [26,27].
Urine was collected up to 32 and 120 hours after infusion
began for treatments 1 and 2, re s p e c t i v e l y. Plasma and urine
aliquots were stored at –20°C until analysis. CTX, 4 H C / a l d o-
phosphamide, and thiotepa concentrations were measure d
using gas chromatography as described [26-30]. Are a - u n d e r-
t h e - c u rve (AUC) values were calculated using the linear
trapezoidal rule as described by Chiou [31]. CTX and
4HC/aldophosphamide AUC values from these patients
w e re previously included in a larger pharmacokinetic analysis
of patients with advanced breast cancer treated at our institu-
tion with high-dose chemotherapy followed by autologous
bone marrow transplantation [26,27,32].
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L a b o r a t o r y Evaluation of Plasma Novobiocin Ability
to Reverse Alkylator Cytoto x i c i t y
A clonogenic assay was used to assess the cytotoxicity of
4HC (a gift of Dr. O.M. Colvin, Duke Comprehensive Can-
cer Center, Durham, NC) in 2 breast cancer cell lines: a wild-
type MCF 7 cell line (a gift of Dr. K. Cowan, National Can-
cer Institute, Bethesda, MD) and a CTX-resistant clone of
the cell line CTX MCF 7 (a gift of Dr. B. Te i c h e r, Dana-Far-
ber Cancer Institute, Boston, MA). The CTX MCF 7 cell
line was selected by weekly 1-hour pulse exposures to escalat-
ing doses of 4HC. These cells demonstrate a 9-fold re s i s t a n c e
to 4HC at 1 log of cell kill, and resistance is stable for up to
2 months without 4HC exposure .
Plasma samples were drawn from patients immediately
b e f o re the first and fourth doses of novobiocin and used as
c o n t rol and novobiocin plasma, re s p e c t i v e l y. The time point
at which the novobiocin plasma was drawn was the same time
point at which novobiocin plasma levels (median 282 µg / m L )
w e re measured in the phase 1 study (7). These plasma sam-
ples were separated by centrifugation, stored at –20°C, and
thawed immediately before use. Cells in exponential gro w t h
w e re released with trypsin and suspended in these plasma
samples 24 hours before, during, and 24 hours after a 1-hour
e x p o s u re to varying concentrations of 4HC to determine the
impact of novobiocin in the plasma on 4HC dose-re s p o n s e
c u rves. After drug exposure, the cells were rinsed 3 times in
p h o s p h a t e - b u ff e red saline and plated in duplicate at 3 dilu-
tions in fresh medium with 10% fetal calf serum for colony
f o rmation. Cells were incubated for 14 days, fixed with 25%
methanol, and stained with crystal violet. Colonies with
> 5 0 cells were scored visually by micro s c o p y. The concentra-
tion of 4HC re q u i red to inhibit clonogenic growth by 90%
( I C9 0) in each cell line was calculated from these re s u l t s .
Statistical Anal y s i s
Survival was measured from the date of PBSC infusion
to the date of death or analysis. PFS was defined as the
i n t e rval between the date of PBSC infusion and first evi-
dence of disease progression. Event time distributions were
estimated using the method of Kaplan and Meier [33]. All
results are presented as of May 7, 1999. Cox model statisti-
cal analysis was done to assess the relationship of both OS
and PFS with CTX, 4HC, or thiotepa AUC values. 
RESULTS
Patient Characteristics
Between March 1993 and August 1995, 43 women were
re g i s t e red to this study. One patient developed re c u rre n t
breast cancer after induction chemotherapy and was there-
fore ineligible for enrollment. A second patient manifested
disease pro g ression during therapy for PBSC mobilization
and did not continue on the protocol. Forty-one women
completed all protocol therapy and were available for long-
term follow-up. Patient characteristics are listed in Table 1.
The median age was 45 years (range, 30-61 years). Four
women had stage IIIB disease, and 37 had stage IV bre a s t
c a n c e r. The median number of re c u rrent disease sites
( l o c o regional, bone, or visceral) in stage IV patients was 1.
Of the patients with stage IV disease, 21 (57%) had 1 site of
involvement, 12 (32%) had 2 sites, and 4 (11%) had disease
in 3 sites. Prior chemotherapy (pre-induction chemotherapy)
and hormonal exposure are shown in Table 1. In patients
with stage IV disease, 2 of 38 (5%) had no evidence of dis-
ease (NED) before induction chemotherapy, and 8 of 38
(21%) had a CR after induction chemotherapy. In addition, 8
of the 26 women (1 patient died in hospital) with a PR after
induction chemotherapy converted to CR after high-dose
t h e r a p y. Median time from PBSC infusion to date of analysis
was 64.9 months (range, 43.7-72.9 months) with a median
follow-up of 21.5 months (range, 0.2-70.6 months).
Nine patients (2 in stage IIIB and 7 in stage IV)
remained in CR at the time of analysis. Of the 7 stage IV
patients free of disease, 2 were stage IV NED pre-induction
c h e m o t h e r a p y, 4 achieved a CR with induction chemo-
t h e r a p y, and 1 converted to CR after high-dose therapy.
The median follow-up in the group of patients who remain
d i s e a s e - f ree is 61.6 months (range, 44-70.6 months). PFS
Table 1. Patient Characteristics (n = 41)
n %
Age range, y
30-39 12 29
40-49 20 49
50-59 8 20
60-69 1 2
Estrogen receptor status
Positive 15 37
Negative* 26 63
Disease stage
IIIB 4 10
IV 37 90
Stage IV patients
Disease sites
Locoregional 28 76
Bone 10 27
Visceral 19 51
Number of disease sites per patient
1 Site
Locoregional 14 38
Bone 0 0
Visceral 7 19
2 Sites
Locoregional and bone 4 11
Locoregional and visceral 6 16
Bone and visceral 2 5
3 Sites
Locoregional, bone, and visceral 4 11
Chemotherapy exposure before 
induction chemotherapy
None 13 34
Adjuvant 22 58
Adjuvant and metastatic 3 8
Previous hormonal therapy
Yes 15 39
No 23 61
Response to induction chemotherapy
Partial 28 76
No evidence of stage IV disease 2 5
before induction therapy
Complete 8 21
*<10 fmol/mg cytosolic protein.
338
and OS curves are depicted in Figure 1. The median times
for PFS and OS were 10 months (range, 0.2-0.6 months)
and 21.5 months (range, 0.2-70.6 months), respectively.
To x i c i t i e s
Toxicities are listed in Table 2. Toxicities following CTX
therapy for PBSC mobilization (treatment 1) included neu-
t ropenic fever with negative blood cultures (13 patients),
acute renal failure (1 patient), and catheter-related thrombo-
sis (1 patient). The episode of acute renal failure was com-
pletely reversible and believed to be secondary to the use of
ibuprofen, which was given as part of the regimen for PBSC
mobilization. No stem cell mobilization–associated toxicity
prevented a patient from receiving high-dose therapy.
T h e re was 1 therapy-related death after high-dose
chemotherapy. The patient had respiratory decompensation
approximately 18 hours after completion of infusional CTX
and thiotepa with resultant re s p i r a t o ry and cardiac arre s t
and secondary anoxic brain damage. The patient was main-
tained on a respirator with maximal support (including rein-
fusion of PBSCs) for 1 week. The patient was then extu-
bated and died 6 days after PBSC reinfusion. No autopsy
was perf o rmed. Unfort u n a t e l y, this patient did not have
pharmacokinetic determination to assess how drug disposi-
tion may have contributed to her outcome.
After high-dose therapy, aplasia and fever were univer-
sal, and all patients were given empiric bro a d - s p e c t ru m
antibiotics. Infectious complications included 5 positive
blood cultures, 3 episodes of oropharyngeal herpes simplex
viral infection, 1 fungal pneumonia (diagnosed by character-
istic computed tomography scan findings and clinical
response to amphotericin B therapy), and 1 derm a t o m a l
varicella zoster reactivation. Additional toxicity included
1 episode of hemorrhagic cystitis.
Rehospitalizations not related to re c u rrent disease
o c c u rred in 6 patients. Indications for readmission included
c a t h e t e r- related infection (n = 2), systemic varicella infection
(n = 1), congestive heart failure (n = 1), and a severe desqua-
mative rash related to sulfamethoxazole/trimethoprim (n = 1).
Pharmacokinetic Anal y s i s
Blood samples for determination of plasma CTX concen-
trations during treatments 1 and 2 and thiotepa levels during
t reatment 2 were available in 35 (85%) of the 41 p a t i e n t s .
Plasma 4HC/aldophosphamide measurements for both tre a t-
ments were obtained in 10 (24%) patients. Urine CTX con-
centrations were determined in 26 (63%) patients for both
t reatments. The median CTX AUC value for treatment 1
was 257 mmol/L per min (range, 156-689 mmol/L per min).
Median CTX and thiotepa AUC values for t re a t m e n t 2 w e re
553 mmol/L per min (range, 264-974 mmol/L per min) and
1 1 mmol/L per min (range, 3-77 mmol/L per min), re s p e c-
t i v e l y. Median urine CTX excretion was 23% (range, 4%-
36%) for treatment 1 and 32% (range, 10%-46%) for tre a t-
ment 2. Median total CTX dose minus urine CTX amounts
(which re p resents active and inactive metabolites of CTX in
the blood) were 4454 mg (range, 3750-5090 mg) for tre a t-
ment 1 and 5902 mg (range, 5338-6729 mg) for treatment 2.
Median CTX AUC values were similar to their mean values
(data not shown), whereas median thiotepa AUC was 11 ver-
sus a mean of 26. Thiotepa AUC values show a large interpa-
tient variability, with a range of 3 to 77 mmol/L per min. The
values shown in Figure 2 demonstrate an asymmetrical distri-
bution skewed toward higher thiotepa AUC values. Unpub-
Figure 1. Actuarial progression-free and overall survival curves for evaluable patients (n =  41).
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lished data from these and additional patients treated at this
institution with the same dose and schedule of thiotepa and
CTX without novobiocin demonstrated no alteration of
thiotepa pharmacokinetics by novobiocin. 
T h e re was no statistically significant relationship between
PFS and any of the AUC values, with P values of .71 and .74
for CTX (treatments 1 and 2, respectively) and .92 for
thiotepa. Nor was any statistically significant re l a t i o n s h i p
found with OS and CTX or thiotepa AUC values (P values .17
and .12 for CTX [treatments 1 and 2, respectively] and .42 for
thiotepa). Median plasma 4HC/aldophosphamide AUC levels
w e re comparable in both treatments at 6.3 and 6.9 mmol/L
per min. There was no statistically significant re l a t i o n s h i p
between 4HC/aldophosphamide AUC and PFS or OS. Risk
ratios (confidence intervals) for 4HC/aldophosphamide for
t reatment 1 were 0.67 (0.14-2.75) and 0.70 (0.14-2.85) for OS
and PFS, re s p e c t i v e l y. For treatment 2, they were 2.52 (0.61-
12.51) and 3.81 (0.81-27) for OS and PFS, re s p e c t i v e l y.
In Vitro Reversal of Alkylator Resistance
Plasma samples from 12 patients were available for eval-
uation of in vitro reversal of alkylator resistance. Two of
them had stage IIIB disease and 10 had stage IV. Two of
1 0 patients with stage IV disease had a CR to induction
chemotherapy. Two of the 12 women remain disease free, 1
with stage IIIB disease and 1 with stage IV (who achieved a
CR to induction chemotherapy).
Plasma samples collected after 36 hours of novobiocin
therapy from all 12 patients were able to augment 4HC-
induced cytotoxicity. The results from these studies are
shown in Table 3 and Figure 3. Mean IC9 0 values of 4HC
t reatment in the parental wild-type breast cancer cell line
d e c reased 5.7-fold after exposure to post-novobiocin plasma
samples. The CTX-resistant cell line also demonstrated an
i n c reased sensitivity to 4HC after exposure to the plasma
collected after initiation of novobiocin. There was a 5.1-fold
reduction in the mean IC9 0 in this group, thus reducing the
4HC concentration re q u i red to achieve an IC9 0 down to a
comparable level in the pre-novobiocin group of the wild-
type cell line (58 and 60 µmol/L, respectively). Plasma
derived from the 2 women who remain in CR did not
demonstrate any consistently increased effect of novobiocin-
augmented alkylator cytotoxicity in either cell line tested. 
DISCUSSION
The role of high-dose therapy in the management of
b reast cancer remains to be defined. Conventional-dose
chemotherapy produces response rates of 40% to 65% in
women with metastatic disease, but only 10% to 25% are
complete responses [34,35]. The duration of these responses
is measured in months, and almost all patients die of their
disease a median of 18 to 24 months from diagnosis [36,37].
High-dose therapy with PBSC or bone marrow support has
resulted in increased response rates, including complete
responses, but has not been shown to significantly alter
median time to disease progression or overall survival com-
p a red with historical controls treated with conventional-dose
chemotherapy [38]. Although 10% to 20% of the women
t reated with high-dose therapy appear to have durable com-
plete responses, it is unclear if this is a larger fraction than
might be observed in similar patients treated with standard -
dose combination chemotherapy [39]. Indeed, a recent study
by Stadtmauer et al. [40] randomized women with chemo-
sensitive metastatic breast cancer to high-dose therapy and
autologous transplant versus maintenance chemotherapy.
The median OS and PFS of 24 months and 9.6 m o n t h s ,
re s p e c t i v e l y, for the transplant group did not differ signifi-
cantly from median OS and PFS of 26 and 9 months, re s p e c-
t i v e l y, for the maintenance group. Theref o re, inherent or
a c q u i red drug resistance in this setting results in ultimate
t reatment failure for the majority of patients. 
This study addressed whether the addition of novo-
biocin, an agent known to reverse alkylator drug resistance
in experimental models, to a high-dose alkylator regimen in
women with advanced breast cancer would suggest an
i n c reased clinical efficacy and warrant additional clinical
evaluation. PFS or OS was not substantially altered by the
addition of novobiocin to high-dose chemotherapy com-
p a red with historical controls treated with high-dose
chemotherapy. An analysis by Antman et al. [6] of high-dose
therapy for stage IV breast cancer using data derived from
the Autologous Blood and Marrow Transplant Registry
reported median OS and PFS of 18 and 9 months, respec-
t i v e l y. In our study, the median OS was 21.5 months, and
PFS was 10 months. Our study results there f o re do not
significantly differ from those obtained in patients tre a t e d
with high-dose alkylator therapy alone in this historical
Table 2. Toxicity (n = 41)*
Toxic death 1 (2)
Hospital days
Total 32 (16-150)
After stem cell reinfusion 18 (6-139)
Hematologic toxicity
Days to neutrophil count >500 15 (11-57)
Days to last platelet transfusion 11 (7-412)
Infectious complications†
Episodes of neutropenic fever after treatment 1 13 (32)
Positive blood cultures after treatment 1 0 (0)
Positive blood cultures after treatment 2 5 (12)
Readmissions after BMT discharge‡ 6 (15)
Gastrointestinal toxicity (n = 0)
Days of hyperalimentation 16 (0-37)
Days of parenteral narcotic 11 (0-25)
Mucositis grade
None 3 (8)
I 1 (3)
II 3 (8)
III 1 (3)
IV 32 (80)
Cardiac toxicity (n = 40)
Left ventricular ejection fraction
Pretreatment 59 (45-76)
Day 8 61 (36-72)
Postdischarge 60 (18-73)
*Data are n (%) or median (range).
†Treatment 1 consisted of cyclophosphamide 4 g/m2 and treatment 2 consisted
of cyclophosphamide 1.5 g/m2 per day and thiotepa 200 mg/m2 per day contin-
uous infusion for 4 days.
‡Not related to disease recurrence.
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database [6,38]. These results also do not differ from OS
and PFS for women with advanced breast cancer tre a t e d
p reviously at our institution with an identical high-dose
alkylator regimen (without novobiocin) and autologous
marrow support (data not shown). Because eligibility criteria
for trial entry and characteristics of this group of women
were similar to those in our previous studies, selection bias
is not likely to play a major role in this particular study.
These results suggest a low likelihood that novobiocin’s
ability to reverse alkylator resistance had a significant bene-
fit in terms of PFS or OS in this patient population. How-
ever, the small sample size cannot exclude the possibility of a
small clinical benefit.
This study also evaluated the pharmacokinetics of
CTX and thiotepa and analyzed their impact, if any, on
PFS and OS. The metabolism of CTX is complex, and
levels of the active product, phosphoramide mustard, are
d et e rmined by metabolism as well as urinary clearance of
the inactive parent compound [41,42]. Studies have
shown increased renal clearance of the parent compound
in the setting of high-dose therapy because of the aggre s-
sive hydration used to prevent bladder toxicity [27,43].
Figure 2. Distribution of thiotepa area-under-the-curve values (n = 35).
Table 3. In Vitro Testing of Patient Plasma Samples for Reversal of Alkylator Resistance*
IC 90 for 4HC, µmol/L
Wild-Type MCF-7 CTX-Resistant MCF-7
Novobiocin Novobiocin
Patient Stage Response† Before After Fold Reduction Before After Fold Reduction
1 IV PR 71 11 6.5 340 54 6.3
2 IIIB† — 60 14 4.3 290 70 4.1
3 IV PR 52 12 4.3 334 41 8.1
4 IV‡ CR 49 4 12.3 290 68 4.3
5 IV PR 52 9 5.8 252 68 3.7
6 IV PR 55 3 18.3 265 60 4.4
7 IV PR 55 9 6.1 290 66 4.4
8 IV PR 64 7 9.1 305 57 5.4
9 IIIB — 41 20 2.1 314 61 5.1
10 IV PR 63 6 10.5 266 63 4.2
11 IV CR 65 15 4.3 305 45 6.8
12 IV PR 93 17 5.5 281 43 6.5
Mean ± SD 60.0 ± 13.2 10.6 ± 5.3 5.7 294.3 ± 26.9 58.0 ± 10.2 5.1
*4HC indicates 4-hydroperoxycyclophosphamide; CR, complete response; IC90, drug concentration that inhibits 90% of colony formation in a clonogenic assay; IV,
intravenous; PR, partial response.
†After induction chemotherapy.
‡Patients who remain in CR. 
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T h e ref o re, significant amounts of the inactive pare n t
compound can be cleared re n a l l y. In addition, there is
significant interpatient variability in the metabolism of
CTX [27,43,44]. There f o re, patient characteristics, re n a l
clearance, concomitant medications, and metabolism all
play a role in determining the extent of exposure to active
d rug for any patient.
CTX and thiotepa AUC values did not demonstrate a
statistically significant correlation with PFS or OS in our
study. Low CTX AUCs may be secondary to increased con-
version into active metabolites, increased metabolism to
inactive products, or renal clearance of the inactive pare n t
compound. Therefore, the active metabolite 4HC was also
measured in a subset of patients; again, no significant corre-
lation with OS or PFS was observed.
Ayash et al. [45] showed that the median AUC values
for CTX in patients treated with high-dose therapy for
metastatic breast cancer were lower for the patients who
developed clinical signs and symptoms of congestive heart
f a i l u re (CHF). These same patients had not reached the
median duration of response at a follow-up of 22 months,
w h e reas patients who had not had CHF and had a higher
median AUC had a median duration of response of only
5 . 2 5 months [45]. Ayash et al. hypothesized that incre a s e d
conversion of CTX to its active metabolites may have
resulted in increased toxicity as well as eff i c a c y, although
metabolites or urinary levels of CTX were not determined.
In contrast, our study failed to show any association between
clinical benefit or toxicity and CTX or 4HC AUC values.
The high-dose regimen in our study was not restricted to
the carboplatin, CTX, and thiotepa regimen used by Ayash
et al., and direct comparison of the 2 trials is thus difficult.
Nonetheless, our results would argue against using CTX or
4HC values to predict patient response or toxicity.
Thiotepa levels demonstrated large interpatient variabil-
ity and an asymmetric distribution. The skewed distribution
of values in this population may be secondary to genetic dif-
ferences in drug metabolism. Although this distribution was
o b s e rved, its clinical relevance remains unclear because
thiotepa AUC values did not correlate with a clinical
response as measured by PFS or OS.
In addition, this study evaluated the ability of patient
plasma samples obtained during novobiocin treatment to
reverse CTX drug resistance in vitro. The assay measure d
CTX-induced cytotoxicity in both CTX-sensitive and -resis-
tant breast cancer cell lines treated with patient plasma sam-
ples obtained before and during novobiocin therapy. Treat-
ment of the cells in vitro with these samples resulted in a
Figure 3. Results of clonogenic studies in both parental and cyclophosphamide-resistant MCF-7 breast cancer cell lines after exposure to patient plasma samples
before and during novobiocin therapy.
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2- to 18-fold decrease of IC90 in the sensitive cell line and a
4- to 8-fold decrease of CTX required to achieve an IC90 in
the resistant cell line. Treatment of the CTX-resistant cell
line resulted in almost 1 additional log cell kill. This level of
activity is consistent with preclinical models.
H o w e v e r, these in vitro results did not translate into
any apparent significant clinical advantage in terms of PFS
and OS. There are several possible explanations for the
lack of correlation between reversal of alkylator re s i s t a n c e
in vitro and clinical response. First, these assays were
accomplished in only 12 of 41 patients. These small num-
bers may not allow for a clinical advantage to be appre c i-
ated. In addition, only 2 of the 12 women are long-term
d i s e a s e - f ree survivors, making it difficult to comment on
any relationship between clinical outcome and in vitro
c y t o t o x i c i t y. Also, the patient population included women
with advanced breast cancer previously treated with
c h e m o t h e r a p y, a time when tumor is likely made up of a
mixed population of cells manifesting multiple genetic and
biochemical abnormalities, which could result in dru g
resistance. Although these patients had chemosensitive dis-
ease, these molecular changes were likely associated with
substantial chemotherapy resistance as suggested by the
high relapse rate. Thus, it is possible that the presumed 1
to 2 log increase in CTX-induced cytotoxicity induced by
novobiocin in this study was still insufficient to overc o m e
d rug resistance in a clinically relevant way in this group of
women with heterogeneous advanced disease. Also, the
e ffects of novobiocin were demonstrated indirectly in an in
v i t ro assay using established cell lines rather then dire c t l y
in an assay against patients’ own tumor cells. The in vitro
evaluation is a surrogate measure of patients’ tumor
response; only actual measurement of tumor cell re s i s t a n c e
to alkylator therapy before and after novobiocin therapy
using serial tumor samples from individual patients would
p rovide direct evidence of novobiocin effects in tumor
cells. Finally, although dose intensity is important in the
t reatment of breast cancer, there may be a dose plateau
beyond which increased dose does not translate into clini-
cal benefit [46,47]. In that case, modulating agents such as
novobiocin might be more useful with standard - d o s e
rather than high-dose therapy.
Although comparison of these results with historical
controls is limited by many confounding factors, our results
do not support evaluating novobiocin in combination with
high-dose alkylator therapy for metastatic breast cancer in a
phase 3 clinical study. However, additional evaluation of the
role of this agent or other compounds that reverse dru g
resistance may be warranted in the setting of women with
advanced breast cancer who have minimal residual disease
or in the adjuvant setting for high-risk patients. Indeed, in
this study, the women who continue in CR had either stage
IIIB disease (2 patients), stage IV NED, or stage IV disease
in CR following induction chemotherapy or high-dose ther-
apy (n = 7). The role of novobiocin, if any, in their response
is impossible to assess because of the small number of
women with these characteristics. Perhaps small increments
in overall cell kill in this setting may translate to increased
progression-free or overall survival. Additional phase 2 stud-
ies in this context may demonstrate increased clinical effi-
cacy and warrant phase 3 evaluation.
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